Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribupatide in Obesity or Overweight Without Diabetes
NCT07284875Phase 3Active, not recruiting
- Sponsor
- Kailera Therapeutics
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Countries
- 10
01
Overview
A Phase 3 trial of ribupatide in obesity, sponsored by Kailera Therapeutics. Started Dec 2025; status: active, not recruiting.
02
Drugs
ribupatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07284875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284875.